Share this
by Jeff Jacques, MD, Chief Medical Officer at Virgin Pulse on September 25, 2023
With obesity affecting 1 in 3 U.S. adults and a staggering $147 billion spent on obesity-related healthcare services annually, the situation can seem daunting. The impact of obesity extends beyond weight, triggering conditions like type 2 diabetes, heart disease, and even cancers. In the battle against this pandemic, GLP-1 medications like Ozempic and Wegovy have earned their status as potential game-changers. But, like most things, they are not free of controversy.
GLP-1 medications have shown promising results in catalyzing weight loss yet are often shadowed by issues like high costs and potential risks, such as rebound weight gain.
At Virgin Pulse, we view weight management as a personal, complex journey that goes beyond medication. While effective for some, we believe GLP-1 medications should be seen as an accelerator or kick-start to meaningful weight loss, not a standalone, long-term solution. After all, what about those who do not qualify for GLP-1 treatments? Where do they find their path to sustainable weight management? And is the individual taking a GLP-1 medication supported on their unique journey?
No Comments Yet
Let us know what you think